Key Highlights
- Karyopharm Therapeutics (NASDAQ:KPTI) indicated at USD 0.0311 pre-market on November 10, 2026, down 22.25% from a calculated prior close of USD 0.0400.
- The company filed Chapter 11 on November 2, 2026 with a USD 55 million Bankruptcy loan, and Ayrmid is the lead bidder in a court-supervised sale expected to close in early 2027.
- Nasdaq issued a delisting notice on November 4, 2026; trading is suspended from November 11, 2026 and the ticker is expected to become KPTIQ on an OTC market.
- The plan gives common stockholders no distribution, and the company says it expects its Equity to have no value, after shares fell 83% to USD 0.11 on November 2.
What Moved Karyopharm Pre-Market (-22.25%)
Karyopharm Therapeutics and Subsidiary KPT Texas LLC filed Chapter 11 petitions in the U.S. Bankruptcy Court for the Southern District of Texas, Houston Division, on November 2, 2026, together with a prepackaged plan. Published coverage that day said shares fell 83% to USD 0.11, a Market Value near USD 2.5 million. Nasdaq delivered a delisting notice on November 4, 2026 citing Listing Rules 5101, 5110(b) and IM-5101-1, and the company said it will not appeal. Trading on Nasdaq is suspended at the open on November 11, 2026, with OTC quotes expected under KPTIQ on or after that date. The pre-market price of USD 0.0311 is 22.25% below the calculated prior close of USD 0.0400 from Monday, November 9. The company said holders of common stock and its 0% Series A Convertible Perpetual Preferred Stock will receive no payment under the plan.
The Rationale: Bankruptcy Sale and Equity Wipe-Out
The catalyst is the bankruptcy process, not new Tuesday news. Ayrmid, parent of Gamida Cell, is the lead bidder, no bid amount has been disclosed, and a court-supervised auction will run while the company operates on a USD 55 million Loan from existing lenders. Karyopharm had USD 15.8 million of Debt coming due and had reached a forbearance deal. In 2025 it reported about USD 115 million of net Xpovio sales, a loss of about USD 196 million and an accumulated Deficit of USD 1.8 billion; cash was USD 55 million on June 30, 2026. As general context, when a company states that equity will be cancelled with no recovery, remaining shares often trade on speculation, forced selling by funds that cannot hold Delisted names, and the final-session rush before a suspension. These are general mechanisms, not confirmed causes of today's drop.
Valuation, Liquidity and Risks for Karyopharm
Published data from October 22, 2026 showed 22.68 million shares, a 52-week price change of -91.51%, total debt of USD 328.53 million, cash of USD 65.11 million and short interest of 6.06 million shares, or 26.70% of shares. At USD 0.0311 the market value is about USD 0.7 million (calculated), against Enterprise value of USD 275.81 million on that earlier page. Spreads at sub-penny-scale prices are wide, a small number of trades can move the quote, and a one-tick change alters the move size. The risks are total loss for equity holders, trading halts, OTC illiquidity after November 11 and sharp reversals. Nothing here implies the move will continue.
Where Things Stand
Karyopharm Therapeutics (NASDAQ:KPTI) is down 22.25% pre-market on November 10, 2026 because the company is in Chapter 11, Nasdaq will suspend trading on November 11, 2026, and the plan says common equity should have no value. The price of USD 0.0311 reflects a market pricing very small residual odds. Anyone holding shares faces extreme Volatility and likely zero recovery under the filed plan.






Please wait processing your request...